dalbavancin
- RxCUI
- 1539239
- RxNorm name
- dalbavancin
- Term type
- IN
- Status
- Active
- Updated
- 2026-06-04 07:08:23
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 072014
- Active start
- 072014
- Multiple ingredient
- NO
- Branded
- NO
Source Vocabulary Codes#
| Code type | Value | Category |
|---|---|---|
| PRESCRIBABLE | Y | ATTRIBUTES |
| RXNAV_STR | dalbavancin | NAMES |
| RxNorm Name | dalbavancin | NAMES |
| TTY | IN | ATTRIBUTES |
| SPL_SET_ID | 1f4a5924-96d7-445a-b75f-2c0e1ffd2dea | CODES |
| SPL_SET_ID | 2a20d077-a5ba-4af3-a2d6-499c25b816d8 | CODES |
| SPL_SET_ID | 2c2ec45e-48a2-4887-8ab0-9244eb39a394 | CODES |
| SPL_SET_ID | 4b4674d8-4d1e-4728-8465-d42ada33fa5c | CODES |
| SPL_SET_ID | 966995bb-9d92-434d-b75a-1786072b81c9 | CODES |
| UNII_CODE | 808UI9MS5K | CODES |
| RxCUI | 1539239 | CODES |
| MMSL_CODE | BN399068 | CODES |
| MMSL_CODE | GNd08264 | CODES |
UNII Substances#
| UNII | Preferred term | Registry number | Source |
|---|---|---|---|
| 808UI9MS5K | DALBAVANCIN | 171500-79-1 | tbl_unii_list |
| 808UI9MS5K | DALBAVANCIN | 171500-79-1 | tbl_unii_list |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Dalbavancin | DALBAVANCIN | Somerset Therapeutics, LLC | f4c0bd0f-03c2-4ce5-bcc2-b58f21ce75c1 | 2026-07-28 | Warnings, Adverse reactions | DALBAVANCIN |
| Dalbavancin | DALBAVANCIN | BE Pharmaceuticals Inc. | 6c188995-ab05-45c3-a3af-5b1bcd655fdc | 2026-06-12 | Warnings, Adverse reactions | DALBAVANCIN |
| Dalbavancin | DALBAVANCIN | Meitheal Pharmaceuticals Inc | 966995bb-9d92-434d-b75a-1786072b81c9 | 2025-12-03 | Warnings, Adverse reactions | DALBAVANCIN |
| Dalbavancin | DALBAVANCIN | Teva Pharmaceuticals, Inc. | 1f4a5924-96d7-445a-b75f-2c0e1ffd2dea | 2025-10-06 | Warnings, Adverse reactions | DALBAVANCIN |
| DALVANCE | DALBAVANCIN | Allergan, Inc. | 4b4674d8-4d1e-4728-8465-d42ada33fa5c | 2025-01-13 | Warnings, Adverse reactions | DALBAVANCIN |
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | J01XA | Glycopeptide antibacterials | ATC1-4 | dalbavancin | |
| FDASPL | D000077427 | Lipoglycopeptides | CHEM | has_chemical_structure | dalbavancin |
| FDASPL | N0000191281 | Lipoglycopeptide Antibacterial | EPC | has_epc | dalbavancin |
| MEDRT | D017334 | Teicoplanin | CHEM | has_ingredient | dalbavancin |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | dalbavancin |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | dalbavancin hydrochloride |
| MEDRT | D012874 | Skin Diseases, Infectious | DISEASE | may_treat | dalbavancin |
| MEDRT | D012874 | Skin Diseases, Infectious | DISEASE | may_treat | dalbavancin hydrochloride |
| MEDRT | D013203 | Staphylococcal Infections | DISEASE | may_treat | dalbavancin |
| MEDRT | D013203 | Staphylococcal Infections | DISEASE | may_treat | dalbavancin hydrochloride |
| MEDRT | D013290 | Streptococcal Infections | DISEASE | may_treat | dalbavancin |
| MEDRT | D013290 | Streptococcal Infections | DISEASE | may_treat | dalbavancin hydrochloride |
| MEDRT | N0000000150 | Protein Synthesis Inhibitors | MOA | has_moa | dalbavancin |
| MEDRT | N0000000150 | Protein Synthesis Inhibitors | MOA | has_moa | dalbavancin hydrochloride |
| MEDRT | N0000008479 | Decreased Cell Wall Synthesis & Repair | PE | has_pe | dalbavancin |
| MEDRT | N0000008479 | Decreased Cell Wall Synthesis & Repair | PE | has_pe | dalbavancin hydrochloride |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | GENERAL_CARDINALITY | SINGLE |
| ATTRIBUTES | PRESCRIBABLE | Y |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |
| ATTRIBUTES | TTY | IN |
| CODES | ATC | J01XA04 |
| CODES | DRUGBANK | DB06219 |
| CODES | MMSL_CODE | BN399068 |
| CODES | MMSL_CODE | GNd08264 |
| CODES | RxCUI | 1539239 |
| CODES | SNOMEDCT | 703917001 |
| CODES | SNOMEDCT | 703919003 |
| CODES | SPL_SET_ID | 1f4a5924-96d7-445a-b75f-2c0e1ffd2dea |
| CODES | SPL_SET_ID | 2a20d077-a5ba-4af3-a2d6-499c25b816d8 |
| CODES | SPL_SET_ID | 2c2ec45e-48a2-4887-8ab0-9244eb39a394 |
| CODES | SPL_SET_ID | 4b4674d8-4d1e-4728-8465-d42ada33fa5c |
| CODES | SPL_SET_ID | 966995bb-9d92-434d-b75a-1786072b81c9 |
| CODES | UNII_CODE | 808UI9MS5K |
| CODES | VUID | 4025243 |
| NAMES | RXNAV_STR | dalbavancin |
| NAMES | RxNorm Name | dalbavancin |
| SOURCES | Source | Anatomical Therapeutic Chemical |
| SOURCES | Source | Drug Bank |
| SOURCES | Source | Gold Standard Alchemy |
| SOURCES | Source | Metathesaurus FDA Structured Product Labels |
| SOURCES | Source | Multum MediSource Lexicon |
| SOURCES | Source | National Drug Data File Plus Source Vocabulary |
| SOURCES | Source | US Edition of SNOMED_CT |
| SOURCES | Source | Veterans Health Administration National Drug File |